Sign In
Buy JNJ
$244.88
+3.88 (+1.61%)
At Close: Jun 25, 2026
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson
10:15am, Saturday, 27'th Jan 2024
UnitedHealth Group is an undervalued stock with some promising long-term growth prospects. Johnson & Johnson's business is leaner without its consumer health segment, and it has been focusing more on
Dividend Dynamos- 7 Stocks Delivering Consistent Cash Flow This Year
05:03pm, Friday, 26'th Jan 2024
Investing in the stock market isn't without the risks, but what if you could generate extra income from your investment? If you are a risk-averse investor like me and want to build a retirement portfo
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
04:17pm, Friday, 26'th Jan 2024
The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.
JNJ, LLY: Health Care Earnings To Watch
01:08pm, Friday, 26'th Jan 2024
Eli Lilly (LLY) is up over 80% year-over-year. Lee Brown discusses health care stocks.
Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation
10:31am, Friday, 26'th Jan 2024
J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.
Better Dividend Stock to Buy Now: Johnson & Johnson vs. Verizon
07:19am, Thursday, 25'th Jan 2024
Johnson & Johnson reported strong earnings growth last year but its shares only offer a 3% dividend yield at recent prices. Verizon offers a big 6.3% dividend yield at recent prices but its bottom lin
7 Dividend Stocks to Buy and Never Sell: January 2024 Edition
06:22am, Thursday, 25'th Jan 2024
One of the best ways to create wealth is finding the right dividend stocks to buy and hold. No other asset class has performed as well as buying equities, not gold, not bonds, not real estate.
Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'
10:20pm, Wednesday, 24'th Jan 2024
Johnson & Johnson reported strong Q4 FY23 results and reaffirmed guidance for FY24, exceeding expectations. The company's pharmaceutical business has the potential for 5-7% long-term growth, driven by
Washington state reaches nearly $150 million settlement with Johnson & Johnson over opioid crisis
09:22pm, Wednesday, 24'th Jan 2024
OLYMPIA, Wash. — The Washington state attorney general announced a $149.5 million settlement Wednesday with drug maker Johnson & Johnson, more than four years after the state sued the company over i
J&J Sees Surge in MedTech Sales Post-Kenvue Split
09:20pm, Tuesday, 23'rd Jan 2024
Six months after parting ways with its consumer health unit, Kenvue, Johnson & Johnson has reported total sales of $21.4 billion for the last quarter of 2023, a 7.3% increase from the corresponding q
3 Stocks to Consider After Beating Earnings Estimates
04:16pm, Tuesday, 23'rd Jan 2024
With the earnings season now in full force, valuable data to gauge the broader economy will be rolling in.
J&J's Spravato success confirms commercial viability of psychedelics for mental health
03:21pm, Tuesday, 23'rd Jan 2024
The commercial success of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato for use in treatment-resistant depression and major depressive disorder with suicidal ideation bodes well for o
Drug Pipeline Is Well Positioned for 2024, Says J&J CFO
02:47pm, Tuesday, 23'rd Jan 2024
Joseph Wolk, Johnson & Johnson Chief Financial Officer, says the drug pipeline is well positioned for this year. He also comments on their earnings and the use of artificial intelligence in medicine a
Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million
01:59pm, Tuesday, 23'rd Jan 2024
The settlement does not resolve the tens of thousands of lawsuits alleging that J&J's talc-based products caused cancer.
Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript
01:14pm, Tuesday, 23'rd Jan 2024
Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript
